Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Transcription elongation factor A like 3 (TCEAL3) is a nuclear phosphoprotein from the TCEAL (transcription elongation factor A (SII)-like) gene family[1][3][5]. This protein contains a TFA domain and may modulate gene transcription in a promoter-dependent manner. TCEAL3, like other family members, is thought to fine-tune the expression of target genes, possibly intersecting with canonical signaling pathways and cellular regulatory networks. It is encoded on the X chromosome, and alternative splicing leads to multiple transcript variants encoding a single protein isoform. TCEAL3 has been associated with certain diseases, such as Pelizaeus-Merzbacher Disease and severe congenital neutropenia 7, but definitive functional roles in disease are not established. There is no evidence that TCEAL3 is a therapeutic receptor, enzyme, transporter, or direct drug target[1][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Transcription elongation factor A like 3 (TCEAL3).